Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Phase 3 study shows zavegepant can relieve migraine pain in 15 minutes

By Brian Buntz | February 16, 2023

Zavegepant

[Zavegepant image from PubChem]

The Lancet has published Phase 3 study results for zavegepant, an investigational nasal spray for the acute treatment of migraine. The study found that a single 10 mg intranasal dose of zavegepant was more effective than placebo for pain relief and freedom from the most bothersome symptom at two hours post-dose.

Zavegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is a protein involved in transmitting pain signals in the brain.

Zavegepant’s nasal formulation could be particularly valuable for migraine patients who experience nausea and difficulty swallowing.

Zavegepant is now a Pfizer asset

Pfizer (NYSE:PFE) acquired the asset through last year’s purchase of Biohaven Pharmaceutical Holding Company (NYSE:BHVN), which had commercialized the dual-acting migraine therapy Nurtec ODT (rimegepant).

In the recent Phase 3 study of zavegepant, the novel CGRP receptor antagonist provided relief from migraine pain within 15 minutes, with effects lasting up to 48 hours for many patients. The drug was well-tolerated, and investigators received no reports of serious adverse events.

The study authors note that further trials would be needed to determine the drug’s long-term safety and its consistency in managing future migraine attacks.

Bristol-Myers Squibb initially discovered the drug.

Biohaven filed a new drug application (NDA) for zavegepant in early 2022. FDA could approve the drug in the first quarter of 2023.

Annual sales could surpass $200M by 2030

Annual U.S. sales of zavegepant could reach $206.8 million by 2030, according to GlobalData. In addition, the analyst firm noted that zavegepant’s intranasal formulation could provide a competitive advantage, especially for patients with migraine-related nausea and dysphagia who cannot take oral gepants such as AbbVie’s Ubrelvy (ubrogepant) or Biohaven’s Nurtec (rimegepant). The firm noted, however, that key opinion leaders (KOLs) it interviewed expressed concerns about the drug candidates’ side effects inherent to nasal sprays. The KOLs also raised questions about its reimbursement.

Roughly 40 million people in the U.S. suffer from migraines. About one billion people worldwide have the condition.

CGRP receptor antagonists have emerged as an important treatment option for migraine patients, but the market for the drugs has become increasingly crowded over the past five years. Notable medications in the class include the following:

  • Aimovig (erenumab): Developed by Amgen and Novartis, erenumab became the first CGRP antagonist to win FDA approval as a preventive treatment of migraine in adults in 2018.
  • Emgality (galcanezumab): Lilly’s galcanezumab won FDA approval in 2018 as a preventative treatment for migraines. A year later, it won approval for episodic cluster headaches.
  • Ajovy (fremanezumab): Developed by Teva Pharmaceuticals, fremanezumab won FDA approval in 2018. Teva received approval for an Ajovy autoinjector two years later.
  • Qulipta (atogepant): The CGRP antagonist from AbbVie won FDA approval in 2021.

Filed Under: Neurological Disease
Tagged With: zavegepant
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
AI-guided hunt points to PHGDH as an upstream drug target in Alzheimer’s disease
Why smaller, simpler molecular glues are gaining attention in drug discovery
Randy Bateman, MD, talks with research technician Olatayo Ajenifuja about Alzheimer’s Disease research in his lab on January 4, 2024, in the Neuroscience Research Building. MATT MILLER/WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Discontinued Alzheimer’s drug shows surprising long-term promise in genetic form of the disease
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE